Chembio Diagnostics (CEMI) 2.98 $CEMI
Chembio Diagnostics Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 8:31AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the first quarter ended March 31, 2014.
Chembio to Host Conference Call to Discuss First Quarter 2014 Financial Results
GlobeNewswire - Thu Apr 24, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the first quarter of 2014, before the opening of the market on Thursday, May 8, 2014. The Company's 10-Q and earnings press release will be available at 9:15a.m. on our web site.
Chembio Terminates U.S. Distribution Agreement With Alere
GlobeNewswire - Mon Apr 07, 9:00AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, announced today that it notified Alere Inc., formerly Inverness Medical Innovations, Inc. ("Alere", of termination of its U.S. STAT-PAK(R) distribution agreement.
Chembio Diagnostics elects Katherine L. Davis as board chair
M2 - Mon Mar 31, 5:22AM CDT
US-based diagnostic test company Chembio Diagnostics (NasdaqCM:CEMI) disclosed on Friday the appointment of Katherine L. Davis as non-executive chairman of the board.
Chembio Names Katherine L. Davis Chairman of the Board
GlobeNewswire - Fri Mar 28, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC" diagnostic tests for infectious diseases, today named Katherine L. Davis as the Company's non-executive Chairman of the Board. Ms. Davis has been on Chembio's board since 2007, has served on all three board standing committees - audit, nominating and corporate governance, and compensation, including serving as Chair of both the Audit Committee and the Nominating And Corporate Governance Committee. Ms. Davis will continue to serve as Chair of the Nominating And Corporate Governance Committee, and as a member of both the Audit and Compensation Committees. Dr. Gary Meller, a director of the Company and a member of the Audit Committee since 2005, has been elected as the new Chair of the Audit Committee.
Nasdaq stocks posting largest volume increases
AP - Tue Mar 25, 5:10PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Chembio's HIV 1/2 STAT-PAK(R) Assay Receives CE Mark Approval for Rapid Point-of-Care Detection of HIV
GlobeNewswire - Tue Mar 25, 10:22AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC" diagnostic tests for infectious diseases, announced today that its HIV 1/2 STAT-PAK(R) Assay received CE Mark approval from European regulators. The Chembio HIV 1/2 STAT-PAK(R) Assay is now cleared for commercialization within the European Union for rapid, POC detection of HIV.
Chembio Diagnostics hires John Sperzel as president & CEO
M2 - Mon Mar 17, 6:24AM CDT
Diagnostic company Chembio Diagnostics (NasdaqCM:CEMI) disclosed on Friday the election of John Sperzel as its president and CEO.
John Sperzel Appointed as President and CEO of Chembio Diagnostics
GlobeNewswire - Fri Mar 14, 8:09AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC" diagnostic tests for infectious diseases, today announced the appointment of John Sperzel as President and CEO, effective March 13, 2014.
Chembio Diagnostics announces record 2013 revenues of USD29.55m and tenth consecutive year of double-digit organic revenue growth
M2 - Fri Mar 07, 4:41AM CST
Diagnostic tests company Chembio Diagnostics (NasdaqCM:CEMI) stated on Thursday that its net income was USD531,000 (USD0.06 per diluted share) for year ended 31 December 2013.
Chembio Diagnostics Reports 2013 Financial Results
GlobeNewswire - Thu Mar 06, 8:24AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the quarter and year ended December 31, 2013, which include record revenues, and a tenth consecutive year of double-digit organic revenue growth.
Chembio Diagnostics, Inc. to Host Fourth Quarter Earnings Webcast Live on Thursday, March 6, 2014
ACCESSWIRE - Wed Mar 05, 8:35AM CST
MEDFORD, NY / ACCESSWIRE / March 5, 2014 / Chembio Diagnostics, Inc. (CEMI) will host a live webcast to discuss the results of the fourth quarter 2013, to be held Thursday, March 6, 2014 at 10:00 AM Eastern Time.
Chembio to Host Conference Call to Discuss 2013 Financial Results
GlobeNewswire - Thu Feb 20, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the year of 2013, before the open of the market on Thursday, March 6, 2014. The Company's 10-K and earnings press release will be available by 9:00 a.m. on our web site.
Chembio Diagnostics Inc & RVR Diagnostics enters into agreements in Southeast Asia, with access to new markets for the patented DPP technology
M2 - Thu Feb 13, 6:12AM CST
Diagnostic tests company Chembio Diagnostics Inc (NasdaqCM:CEMI) said on Wednesday that it has signed a license as well as a manufacturing agreement for its patented DPP technology with RVR Diagnostics SDN BHD based in Malaysia.
Chembio Enters Agreements With RVR in Southeast Asia
GlobeNewswire - Wed Feb 12, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC" diagnostic tests for infectious diseases, announced today that it has entered into two agreements with RVR Diagnostics SDN BHD ("RVR", a privately-held company in Malaysia. The agreements support Chembio's strategy of establishing a market presence in Asia, in collaboration with RVR as a licensee, distributor, and contract manufacturer. The agreements grant exclusive distribution rights to RVR in certain countries in the region and enable RVR to manufacture Chembio's DPP(R) HIV 1/2 Assay and DPP(R) HIV-Syphilis Assay and potentially other products developed by Chembio incorporating its patented DPP(R) technology.
Chembio Provides Update on DPP(R) HIV 1/2 Assay CLIA Waiver Application
GlobeNewswire - Mon Feb 10, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care diagnostic tests for infectious diseases, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) concerning the company's CLIA waiver application for its DPP(R) HIV 1/2 Assay. The DPP(R) HIV 1/2 Assay was approved by the FDA for professional use under an approved Pre-Marketing Application in December 2012. During 2013 untrained user studies were performed in support of a CLIA waiver application which was filed with the FDA at the end of November. During a recent discussion, the FDA indicated that additional new infections should be detected to strengthen Chembio's data that the DPP HIV 1/2 Assay performs equivalently in the hands of the untrained user as compared to the professional user. Chembio is currently working with the FDA to define the specific additional requirements necessary for satisfactory completion of the CLIA waiver application.
Chembio Diagnostics to Present at Three Conferences in January 2014
GlobeNewswire - Thu Jan 09, 2:15PM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC" diagnostic tests for infectious diseases, announced today that Lawrence A. Siebert, Chief Executive Officer, will present at three investor conferences next week. These presentations will provide an overview of the company's products and programs as well as anticipated milestones for 2014. Details regarding these events are as follows:
Chembio to Present at the LD Micro VI: The Main Event Conference
GlobeNewswire - Tue Dec 03, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, announces that Lawrence A. Siebert, Chief Executive Officer, will present at the LD Micro VI: The Main Event Conference to be held December 3 - 5, 2013 in Los Angeles, CA. Mr. Siebert will be presenting at 10:00 am (PT) on Thursday, December 5, Track Four. One-on-one meetings with investors will be held during the conference to discuss the Company's strategy for continued growth. To schedule a meeting with Chembio management, please call conference organizers at 408-457-1042. Attendance at the conference is by invitation only.
Chembio Files for CLIA Waiver with FDA for Point-of-Care DPP(R) HIV 1/2 Assay
GlobeNewswire - Mon Dec 02, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC" diagnostic tests for infectious diseases, has completed its Clinical Laboratory Improvement Amendment ("CLIA" waiver studies for its DPP(R) HIV 1/2 Assay (the "Assay". The Company believes the study results meet CLIA waiver requirements and it has filed the CLIA waiver application with the U.S. Food and Drug Administration ("FDA".
Chembio Board Member Named Winner of Commercialization Award by Purdue University
GlobeNewswire - Thu Nov 21, 1:00PM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC" diagnostic tests for infectious diseases, announced today that Peter Kissinger, Ph.D., a member of the company's board of directors and professor of chemistry at Purdue University, has received the Outstanding Commercialization Award for Purdue University for 2013. The award is given annually to a Purdue University faculty member in recognition of outstanding contributions to, and success with, commercializing the University's research discoveries.
Chembio Diagnostics Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 8:31AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the first quarter ended March 31, 2014.
Chembio to Host Conference Call to Discuss First Quarter 2014 Financial Results
GlobeNewswire - Thu Apr 24, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the first quarter of 2014, before the opening of the market on Thursday, May 8, 2014. The Company's 10-Q and earnings press release will be available at 9:15a.m. on our web site.
Chembio Terminates U.S. Distribution Agreement With Alere
GlobeNewswire - Mon Apr 07, 9:00AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, announced today that it notified Alere Inc., formerly Inverness Medical Innovations, Inc. ("Alere", of termination of its U.S. STAT-PAK(R) distribution agreement. Chembio Diagnostics elects Katherine L. Davis as board chair
M2 - Mon Mar 31, 5:22AM CDT
US-based diagnostic test company Chembio Diagnostics (NasdaqCM:CEMI) disclosed on Friday the appointment of Katherine L. Davis as non-executive chairman of the board.
Chembio Names Katherine L. Davis Chairman of the Board
GlobeNewswire - Fri Mar 28, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, today named Katherine L. Davis as the Company's non-executive Chairman of the Board. Ms. Davis has been on Chembio's board since 2007, has served on all three board standing committees - audit, nominating and corporate governance, and compensation, including serving as Chair of both the Audit Committee and the Nominating And Corporate Governance Committee. Ms. Davis will continue to serve as Chair of the Nominating And Corporate Governance Committee, and as a member of both the Audit and Compensation Committees. Dr. Gary Meller, a director of the Company and a member of the Audit Committee since 2005, has been elected as the new Chair of the Audit Committee. Nasdaq stocks posting largest volume increases
AP - Tue Mar 25, 5:10PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Chembio's HIV 1/2 STAT-PAK(R) Assay Receives CE Mark Approval for Rapid Point-of-Care Detection of HIV
GlobeNewswire - Tue Mar 25, 10:22AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, announced today that its HIV 1/2 STAT-PAK(R) Assay received CE Mark approval from European regulators. The Chembio HIV 1/2 STAT-PAK(R) Assay is now cleared for commercialization within the European Union for rapid, POC detection of HIV. Chembio Diagnostics hires John Sperzel as president & CEO
M2 - Mon Mar 17, 6:24AM CDT
Diagnostic company Chembio Diagnostics (NasdaqCM:CEMI) disclosed on Friday the election of John Sperzel as its president and CEO.
John Sperzel Appointed as President and CEO of Chembio Diagnostics
GlobeNewswire - Fri Mar 14, 8:09AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, today announced the appointment of John Sperzel as President and CEO, effective March 13, 2014. Chembio Diagnostics announces record 2013 revenues of USD29.55m and tenth consecutive year of double-digit organic revenue growth
M2 - Fri Mar 07, 4:41AM CST
Diagnostic tests company Chembio Diagnostics (NasdaqCM:CEMI) stated on Thursday that its net income was USD531,000 (USD0.06 per diluted share) for year ended 31 December 2013.
Chembio Diagnostics Reports 2013 Financial Results
GlobeNewswire - Thu Mar 06, 8:24AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the quarter and year ended December 31, 2013, which include record revenues, and a tenth consecutive year of double-digit organic revenue growth.
Chembio Diagnostics, Inc. to Host Fourth Quarter Earnings Webcast Live on Thursday, March 6, 2014
ACCESSWIRE - Wed Mar 05, 8:35AM CST
MEDFORD, NY / ACCESSWIRE / March 5, 2014 / Chembio Diagnostics, Inc. (CEMI) will host a live webcast to discuss the results of the fourth quarter 2013, to be held Thursday, March 6, 2014 at 10:00 AM Eastern Time.
Chembio to Host Conference Call to Discuss 2013 Financial Results
GlobeNewswire - Thu Feb 20, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the year of 2013, before the open of the market on Thursday, March 6, 2014. The Company's 10-K and earnings press release will be available by 9:00 a.m. on our web site.
Chembio Diagnostics Inc & RVR Diagnostics enters into agreements in Southeast Asia, with access to new markets for the patented DPP technology
M2 - Thu Feb 13, 6:12AM CST
Diagnostic tests company Chembio Diagnostics Inc (NasdaqCM:CEMI) said on Wednesday that it has signed a license as well as a manufacturing agreement for its patented DPP technology with RVR Diagnostics SDN BHD based in Malaysia.
Chembio Enters Agreements With RVR in Southeast Asia
GlobeNewswire - Wed Feb 12, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, announced today that it has entered into two agreements with RVR Diagnostics SDN BHD ("RVR", a privately-held company in Malaysia. The agreements support Chembio's strategy of establishing a market presence in Asia, in collaboration with RVR as a licensee, distributor, and contract manufacturer. The agreements grant exclusive distribution rights to RVR in certain countries in the region and enable RVR to manufacture Chembio's DPP(R) HIV 1/2 Assay and DPP(R) HIV-Syphilis Assay and potentially other products developed by Chembio incorporating its patented DPP(R) technology. Chembio Provides Update on DPP(R) HIV 1/2 Assay CLIA Waiver Application
GlobeNewswire - Mon Feb 10, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care diagnostic tests for infectious diseases, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) concerning the company's CLIA waiver application for its DPP(R) HIV 1/2 Assay. The DPP(R) HIV 1/2 Assay was approved by the FDA for professional use under an approved Pre-Marketing Application in December 2012. During 2013 untrained user studies were performed in support of a CLIA waiver application which was filed with the FDA at the end of November. During a recent discussion, the FDA indicated that additional new infections should be detected to strengthen Chembio's data that the DPP HIV 1/2 Assay performs equivalently in the hands of the untrained user as compared to the professional user. Chembio is currently working with the FDA to define the specific additional requirements necessary for satisfactory completion of the CLIA waiver application.
Chembio Diagnostics to Present at Three Conferences in January 2014
GlobeNewswire - Thu Jan 09, 2:15PM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, announced today that Lawrence A. Siebert, Chief Executive Officer, will present at three investor conferences next week. These presentations will provide an overview of the company's products and programs as well as anticipated milestones for 2014. Details regarding these events are as follows: Chembio to Present at the LD Micro VI: The Main Event Conference
GlobeNewswire - Tue Dec 03, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, announces that Lawrence A. Siebert, Chief Executive Officer, will present at the LD Micro VI: The Main Event Conference to be held December 3 - 5, 2013 in Los Angeles, CA. Mr. Siebert will be presenting at 10:00 am (PT) on Thursday, December 5, Track Four. One-on-one meetings with investors will be held during the conference to discuss the Company's strategy for continued growth. To schedule a meeting with Chembio management, please call conference organizers at 408-457-1042. Attendance at the conference is by invitation only.
Chembio Files for CLIA Waiver with FDA for Point-of-Care DPP(R) HIV 1/2 Assay
GlobeNewswire - Mon Dec 02, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, has completed its Clinical Laboratory Improvement Amendment ("CLIA" waiver studies for its DPP(R) HIV 1/2 Assay (the "Assay". The Company believes the study results meet CLIA waiver requirements and it has filed the CLIA waiver application with the U.S. Food and Drug Administration ("FDA". Chembio Board Member Named Winner of Commercialization Award by Purdue University
GlobeNewswire - Thu Nov 21, 1:00PM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, announced today that Peter Kissinger, Ph.D., a member of the company's board of directors and professor of chemistry at Purdue University, has received the Outstanding Commercialization Award for Purdue University for 2013. The award is given annually to a Purdue University faculty member in recognition of outstanding contributions to, and success with, commercializing the University's research discoveries. 
